牛牛AI助理已提取核心訊息
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
2024年3月7日，Novavax的研發總裁菲利普·杜波夫斯基完成了一項涉及該公司普通股的交易。杜波夫斯基以每股5.61美元的價格出售了9,392股股票，總額爲52,689.12美元。在此次出售之前，他行使了期權收購了19,444股Novavax普通股。這些交易之後，杜波夫斯基在Novavax的直接持股量爲63,834股。此次出售是根據交易代碼執行的，該交易代碼表明通過交付或預扣證券來支付行使價或應納稅額。
2024年3月7日，Novavax的研發總裁菲利普·杜波夫斯基完成了一項涉及該公司普通股的交易。杜波夫斯基以每股5.61美元的價格出售了9,392股股票，總額爲52,689.12美元。在此次出售之前，他行使了期權收購了19,444股Novavax普通股。這些交易之後，杜波夫斯基在Novavax的直接持股量爲63,834股。此次出售是根據交易代碼執行的，該交易代碼表明通過交付或預扣證券來支付行使價或應納稅額。
有用
沒用